A multicenter phase I-II trial was carried out with the aim of identifying the dose-limiting toxicity and the maximum tolerated dose of vinorelbine (VNR) in combination with pegylated liposomal doxorubicin at a dose of 20 mg/m2 every 15 days in patients with metastatic breast carcinoma. In the phase I part of the trial, VNR was given at a dose of 20 mg/m2 every 15 days to a group of 3 patients. In absence of unacceptable toxicity, VNR was escalated to 25, 30, and 35 mg/m2 for subsequent groups of 3 patients, until the dose-limiting toxicity was reached. No case of palmar-plantar erythrodysesthesia was recorded in these patients. Grade 4 neutropenia, grade 3 thrombocytopenia, and grade 3 mucositis were the dose-limiting toxicities recorded in patients treated with VNR 35 mg/m2. These side effects caused a substantial decrease in programmed dose intensity. Therefore 30 mg/m2 was considered the maximum tolerated dose of VNR in combination with pegylated liposomal doxorubicin 20 mg/m2, both given every 15 days. These dosages were employed for the treatment of further 18 patients included in phase II of the study. The overall response rate, calculated according to an intention to treat analysis, was 63% (95% CI: 44–80%), with 2 patients achieving a complete response. The median time to progression was 7.0 months or more (range 2–14 months). Median duration of objective responses was 8.4 months or more. The duration of the 2 complete responses was 9 and 14 months, respectively. Median duration of survival was 16.0 months or more (range from 4.0 to ≧24.0). Toxicity was generally mild and easily manageable. Neutropenia and mucositis were the most frequently recorded side effects. A case of palmar-plantar erythrodysesthesia was recorded in phase II of the study. In conclusion, the maximum tolerated dose of VNR in association with pegylated liposomal doxorubicin is 30 mg/m2 on a bimonthly schedule. Moreover, the combination of VNR and pegylated liposomal doxorubicin is active against metastatic breast carcinoma and is associated with a good toxicity profile. Further studies with this combination regimen are warranted.

1.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1992;339:1–15.
2.
Sledge GW, Antman KH: Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992;19:317–332.
3.
Seidman AD: Chemotherapy for advanced breast cancer: A current perspective. Semin Oncol 1996;23(suppl 2):55–59.
4.
Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490–1495.
5.
Clavel M, Catimel G: Breast cancer: Chemotherapy in the treatment of advanced disease. Eur J Cancer 1993;29A:589–604.
6.
Carmo-Pereira J, Costa FO, Henriquez E, Godinho R, Cantinho-Lopes G, Sales-Luis A, Rubens RD: A comparison of two doses of adriamcycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987;56:471–473.
7.
Jones RB, Holland JF, Bhardwaj S, Norton L, Wilfinger C, Strashun A: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987;5:172–177.
8.
Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD, Chapman PJ: A randomized comparison of single agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991;9:2148–2152.
9.
Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA: Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 1991;28:302–307.
10.
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 1988;6:679–688.
11.
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre study. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 1988;6:976–982.
12.
Henderson IC, Harris JR, Kinne DW: Cancer of the breast; in De Vita VT, Hellman S, Rosemberg SA (eds): Cancer. Principles and Practice of Oncology, ed 3. Philadelphia, Lippincott, 1989, pp 1197–1268.
13.
Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R, Valagussa P: Drugs ten years later: Epirubicin. Ann Oncol 1993;4:359–369.
14.
Plosker GL, Faulds D: Epirubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45:788–856.
15.
Gabizon A, Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 1997;54(suppl 4):15–21.
16.
Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezan E, Gabizon A: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999;86:72–78.
17.
Muggia FM: Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997;54(suppl 4):22–29.
18.
Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios D, Gallenshaw J, Dezube BJ: Randomized comparative trial of doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998;16:683–691.
19.
Caponigro F, Comella P, Budillon A, Bryce J, Avallone A, De Rosa G, Comella G: Phase I study of Caelix (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann Oncol 2000;11:339–342.
20.
Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach C, Morrow CP, Burnett A, Muggia FM: Treatment of patients with ovarian carcinoma with pegylated doxorubicin. Cancer 2001;91:90–100.
21.
Baas P, van Meerbeeck J, Grohen H, Schouwink H, Burgers S, Daamen S, Giaccone G: Calyx in malignant mesothelioma: A phase II EORTC trial. Ann Oncol 2000;11:697–700.
22.
Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS: Phase II trial of doxil for patients with metastatic melanoma refractory to front line therapy. Oncol Rep 1999;6:1097–1098.
23.
Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzgmann H, Mossner J, Berr F: A phase II study of pegylated doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000;11:113–114.
24.
Samantas E, Kalofonos H, Linardou H, Nicolaides C, Mylokanis N, Kosmidis P, Skarlos D: Phase II study of pegylated doxorubicin: Inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study. Ann Oncol 2000;11:1395–1397.
25.
Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037–1047.
26.
Alberts DS, Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997;54(suppl 4):30–35.
27.
Berry G, Billingham M, Alderman E, Richardson P, Torti F, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomial doxorubicin. Ann Oncol 1998;9:711–716.
28.
Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovic S: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998;4:1567–1571.
29.
Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK: Relationship of dose intensity to the induction of palmar-plantar erythrodysesthesia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999;18:17–26.
30.
Skubitz KM, Skubitz AP: Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998;9:45–50.
31.
Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O’Rourke M, Budman D, Bigley J, Hohneker J: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567–2574.
32.
Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hoksin J: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722–2730.
33.
Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Mayelin C, Ruoesse J, Pouillart P, Turz T: Phase II trial of vinorelbine/doxorubicin as first line therapy of advanced breast cancer. J Clin Oncol 1994;12:1765–1770.
34.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207–214.
35.
Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65–74.
36.
Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul L, Wolley PV, Rahman A: Antitumor activity of liposome-encapsulated doxorubicin in breast cancer: Phase II study. J Natl Cancer Inst 1990;82:1706–171.
37.
Ranson MR, Carmichael J, O’Byrne K, Stewart S, Smith D, Howell C: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin. Results of a multicenter randomized phase II trial. J Clin Oncol 1997;15:3185–3191.
38.
Lyass O, Uziely B, Heshing NI, Libson E, Brufman G, Gabizon A: Doxil R in metastatic breast cancer (MBC) after prior chemotherapy: Therapeutic results in two consecutive studies (abstract). Proc Am Soc Clin Oncol 1998;17:156.
39.
Smith F, Barr F, Hendriks C, Burrell L: Phase II study of Doxil R (pegylated liposomal doxorubicin) in doxorubicin resistant metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 1999;18:137.
40.
Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol 1999;17:1435–1441.
41.
Harris L, Winer E, Batist G, Rovira D, Navari R, Lee L: Phase III study of TLC D-99 (liposome-encapsulated doxorubicin) vs free doxorubicin (DOX) in patients with metastatic breast carcinoma (MBC) (abstract). Proc Am Soc Clin Oncol 1998;17:124.
42.
Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Matulonis UA, Parkers LM, Harris LN, Winer EP: Phase I study of doxil and vinorelbine in metastatic breast cancer. J Clin Oncol 1999;10:1113–1116.
43.
Jahanzeb M, Hirsh R: Phase I study of Doxil R in combination with escalating doses of Navelbine R for the treatment of patients with advanced malignancies. Proc Am Soc Clin Oncol 1999;18:215.
44.
Schwonzen M, Kurbacher CM, Mallmann P: Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000;11:681–685.
45.
Valero V, Buzdar AU, Thierault RL, Azarnia N, Fonseca GA, Willey G, Ewer M, Walters RS, Mackay B, Padoloff D, Booser D, Lee L, Hortobagyi GN: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999;17:1425–1434.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.